An immune exhaustion signature predicts prognosis and identifies patients with diffuse large B-cell lymphoma (DLBCL) who derive preferential benefit from chimeric antigen receptor (CAR)-T cell therapy

Cancer Pathogenesis and Therapy · Elsevier

Аннотация

Publication date: September 2026 Source: Cancer Pathogenesis and Therapy, Volume 4, Issue 5 Author(s): Bo Zheng, Wanqian Hu, Ying Fang, Rong Li

Читать у издателя →

Похожие статьи